mesЭкстремальная биомедицинаExtreme Medicine3033-89643033-8972Centre for Strategic Planning of the Federal Medical and Biological Agency10.47183/mes.2021.045mes-89Research ArticleОБЗОРREVIEWКардиоваскулярная коморбидность у пациентов с неалкогольной жировой болезнью печениCardiovascular comorbidity in patients with nonalcoholic fatty liver diseaseЛедовскаяТ. И.LedovskayaT. I.

Волгоград.

Volgograd.

СтаценкоМ. Е.StatsenkoM. E.

Волгоград.

Volgograd.

ТуркинаС. В.TurkinaS. V.

Волгоград.

Volgograd.

КоняхинаТ. А.KonyakhinaT. A.

Волгоград.

Volgograd.

ЮсуповК. С.YusupovK. S.

Волгоград.

Volgograd.

ГорбачеваЕ. Е.GorbachevaE. E.

Елена Евгеньевна Горбачева,

д. 24, к. 125, ул. Ким, г. Волгоград, 400001.

 

Elena E. Gorbacheva, 

24, k. 125, Kim str., Volgograd, 400001.

kasli1@yandex.ruВолгоградский медицинский клинический центр Федерального медико-биологического агентстваРоссияVolgograd Medical Clinical Center of FMBARussian FederationВолгоградский государственный медицинский университетРоссияVolgograd State Medical UniversityRussian FederationВолгоградский медицинский клинический центр Федерального медико-биологического агентства; Волгоградский государственный медицинский университетРоссияVolgograd Medical Clinical Center of FMBA; Volgograd State Medical UniversityRussian Federation2021241020242344854Copyright © Ледовская Т.И., Стаценко М.Е., Туркина С.В., Коняхина Т.А., Юсупов К.С., Горбачева Е.Е., 20242024Ледовская Т.И., Стаценко М.Е., Туркина С.В., Коняхина Т.А., Юсупов К.С., Горбачева Е.Е.Ledovskaya T.I., Statsenko M.E., Turkina S.V., Konyakhina T.A., Yusupov K.S., Gorbacheva E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.extrememedicine.ru/jour/article/view/89

Неалкогольная жировая болезнь печени (НАЖБП) занимает первое место в мире среди болезней печени. Заболевание характеризуется развитием стеатоза и стеатогепатита, в некоторых случаях прогрессирует до цирроза с или без развития печеночной недостаточности и гепатоцеллюлярной карциномы у части пациентов. В настоящее время НАЖБП рассматривают как маркер сердечно-сосудистого риска. Кроме того, она может усугублять течение уже имеющихся сердечно-сосудистых заболеваний. Известно, что развитие структурно-функциональных изменений сердца, печени и сосудов взаимообусловлены и носят взаимоотягощающий характер. Изучено и отрицательное влияние метаболических факторов (дислипидемии, гипергликемии, инсулинорезистентности) на формирование поражения печени, сердца и сосудов, а сочетание НАЖБП и сердечно-сосудистых заболеваний может оказывать влияние на активацию фиброгенеза как в сердце и сосудах, так и в печени.

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. It is characterized by hepatic steatosis and stetohepatitis and in some cases can progress to cirrhosis with or without hepatic failure and hepatocellular carcinoma. At present, NAFLD is deemed a predictor of cardiovascular risk. Besides, it can aggravate pre-existing cardiovascular conditions. Structural and functional changes in the heart, liver and blood vessels are interdependent and mutually aggravating. Metabolic factors (dyslipidemia, hyperglycemia and insulin resistance) contribute to hepatic, cardiac and vascular damage, and NAFLD and comorbid cardiovascular disorders together can activate fibrogenesis in the heart, blood vessels and liver.

неалкогольная жировая болезнь печенижировой стеатознеалкогольный стеатогепатитфиброз печениэндотелиальная дисфункцияnonalcoholic fatty liver diseasefatty steatosisnonalcoholic steatohepatitisliver fibrosisendothelial dysfunctionReferencesЛазебник Л. Б., Голованова Е. В., Туркина С. В., Райхельсон К. Л., Оковитый С. В., Драпкина О. М. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 185 (1): 4–52. DOI: 10.31146/1682-8658-ecg-185-1-4-52.Lazebnik LB, Golovanova EV, Turkina SV, Raikhelson KL, Okovity SV, Drapkina OM, i dr. Nealkogol'naja zhirovaja bolezn' pecheni u vzroslyh: klinika, diagnostika, lechenie. Rekomendacii dlja terapevtov, tret'ja versija. Jeksperimental'naja i klinicheskaja gastrojenterologija. 2021; 185 (1): 4–52. DOI: 10.31146/16828658-ecg-185-1-4-52. Russian.Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology ofnonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84.Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology ofnonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84.Calzadilla Bertot L, Adams L. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016; 17: E774. Available from: https://doi.org/10.3390/ijms17050774.Calzadilla Bertot L, Adams L. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016; 17: E774. Available from: https://doi.org/10.3390/ijms17050774.Loomba R, Adams L. The 20% rule of NASH progres-sion: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019; 70: 1885–8. Available from: https://doi.org/10.1002/hep.30946.Loomba R, Adams L. The 20% rule of NASH progres-sion: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019; 70: 1885–8. Available from: https://doi.org/10.1002/hep.30946.Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюдения DIREG1 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014; 24 (4): 32–8.Drapkina OM, Ivashkin VT. Jepidemiologicheskie osobennosti nealkogol'noj zhirovoj bolezni pecheni v Rossii (rezul'taty otkrytogo mnogocentrovogo prospektivnogo issledovanija nabljudenija DIREG1 01903). Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2014; 24 (4): 32–8. Russian.Ивашкин В. Т., Драпкина О. М., Маев И. В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 6: 31–41.Ivashkin VT, Drapkina OM, Maev IV, i dr. Rasprostranennost' nealkogol'noj zhirovoj bolezni pecheni u pacientov ambulatornopoliklinicheskoj praktiki v Rossijskoj Federacii: rezul'taty issledovanija DIREG 2. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2015; 6: 31–41. Russian.Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230: 258–67.Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230: 258–67.Драпкина О. М., Корнеева О. Н. Метаболический синдром и сердечно-сосудистые заболевания у женщин. Насколько велико влияние пола? Сердце. 2011; 10 (4): 224–8.Drapkina OM, Korneeva ON. Metabolicheskij sindrom i serdechno-sosudistye zabolevanija u zhenshhin. Naskol'ko veliko vlijanie pola? Serdce. 2011; 10 (4): 224–8. Russian.Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61: 1547–54. DOI: 10.1002/hep.27368.Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61: 1547–54. DOI: 10.1002/hep.27368.Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V et al. Fibrosis severity as a determinant of cause-specific mor-tality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018; 155: 443–57. Available from: https://doi.org/10.1053/j.gastro.2018.04.034.Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V et al. Fibrosis severity as a determinant of cause-specific mor-tality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018; 155: 443–57. Available from: https://doi.org/10.1053/j.gastro.2018.04.034.Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural his-tory of nonalcoholic fatty liver disease: a prospective follow-upstudy with serial biopsies. Hepatol Commun. 2: 2017; 199–210. Available from: https://doi.org/10.1002/hep4.1134.Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural his-tory of nonalcoholic fatty liver disease: a prospective follow-upstudy with serial biopsies. Hepatol Commun. 2: 2017; 199–210. Available from: https://doi.org/10.1002/hep4.1134.Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not nash predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67: 1265–73. Available from: https://doi.org/10.1016/j.jhep.2017.07.027.Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not nash predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67: 1265–73. Available from: https://doi.org/10.1016/j.jhep.2017.07.027.Mantovani A, Ballestri S, Lonardo A, et al. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016; 61: 1246–67. Available from: https://doi.org/10.1007/s10620-016-4040-6.Mantovani A, Ballestri S, Lonardo A, et al. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016; 61: 1246–67. Available from: https://doi.org/10.1007/s10620-016-4040-6.Драпкина О. М., Зятенкова Е. В. Оценка ремоделирования сердечно-сосудистой системы и толщины эпикардиального жира у пациентов с хронической сердечной недостаточностью и метаболическим синдромом. Терапевтический Архив. 2016; 88 (2): 64–70.Drapkina OM, Zyatenkova EV. Ocenka remodelirovanija serdechno-sosudistoj sistemy i tolshhiny jepikardial'nogo zhira u pacientov s hronicheskoj serdechnoj nedostatochnost'ju i metabolicheskim sindromom. Terapevticheskij Arhiv. 2016; 88 (2): 64–70. Russian.Дедов И. И., Мельниченко Г. А., редакторы. Ожирение: этиология, патогенез, клинические аспекты. М., 2004; 449 с.Dedov II, Melnichenko GA, redaktory. Ozhirenie: jetiologija, patogenez, klinicheskie aspekty. M., 2004; 449 s. Russian.Ивашкин В. Т., Драпкина О. М., Корнеева О. Н. Клинические варианты метаболического синдрома. МИА. 2011; 208 с.Ivashkin VT, Drapkina OM, Korneeva ON. Klinicheskie varianty metabolicheskogo sindroma. MIA. 2011; 208 s. Russian.Engeli S, Schling P. The adipose-tissue renin-angiotensinaldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003; 35: 807–25.Engeli S, Schling P. The adipose-tissue renin-angiotensinaldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003; 35: 807–25.Стаценко М. Е., Туркина С. В., Шилина Н. Н., Косивцова М. А., Бакумов П. А. Структурно-функциональные особенности печени у больных с неалкогольной жировой болезнью в зависимости от выраженности ожирения. Экспериментальная и клиническая гастроэнтерология. 2018; 9: 38–44.Statsenko ME, Turkina SV, Shilina NN, Kosivtsova MA, Bakumov PA. Strukturno-funkcional'nye osobennosti pecheni u bol'nyh s nealkogol'noj zhirovoj bolezn'ju v zavisimosti ot vyrazhennosti ozhirenija. Jeksperimental'naja i klinicheskaja gastrojenterologija. 2018; 9: 38–44. Russian.Packer M. Atrial fibrillation and heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease. Am J Med. 2020; 133: 170–7. Available from: https://doi.org/10.1016/j.amjmed.2019.09.002.Packer M. Atrial fibrillation and heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease. Am J Med. 2020; 133: 170–7. Available from: https://doi.org/10.1016/j.amjmed.2019.09.002.Manzella D, et al. Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab. 2001; 86: 2769– 74.Manzella D, et al. Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab. 2001; 86: 2769–74.Paolisso G, et al. Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. Am J Cardiol. 1997; 80: 932–37.Paolisso G, et al. Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. Am J Cardiol. 1997; 80: 932–37.Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab. 2005; 90: 6300–2.Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab. 2005; 90: 6300–2.Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019; 7: 313–24. Available from: https://doi.org/10.1016/S2213-8587(18)30154-2.Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019; 7: 313–24. Available from: https://doi.org/10.1016/S2213-8587(18)30154-2.Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015; 21 (22): 6820–34. PMID: 26078558.Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015; 21 (22): 6820–34. PMID: 26078558.Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012; 32: 945–50.Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012; 32: 945–50.Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: apopulationbased cohort study. BMJ Open. 2014; 4: e004973.Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: apopulationbased cohort study. BMJ Open. 2014; 4: e004973.James S, Abate D, Abate K, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 19902017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018; 392: 1789–858. Available from: https://doi.org/10.1016/S0140-6736(18)32279-7.James S, Abate D, Abate K, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 19902017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018; 392: 1789–858. Available from: https://doi.org/10.1016/S0140-6736(18)32279-7.Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018; 115: 557–68. Available from: https://doi.org/10.3238/arztebl.2018.0557.Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018; 115: 557–68. Available from: https://doi.org/10.3238/arztebl.2018.0557.Aneni E, Oni E, Martin S, et al. Blood pressure is associ- ated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015; 33: 1207–14. Available from: https://doi.org/10.1097/HJH.0000000000000532.Aneni E, Oni E, Martin S, et al. Blood pressure is associ- ated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015; 33: 1207–14. Available from: https://doi.org/10.1097/HJH.0000000000000532.Vasunta R, Kesäniemi Y, Ylitalo A, Ukkola O. Primary nonalcoholic fatty liver disease in hypertensive patients. J Hypertens. 2012; 30: 2015–9. Available from: https://doi.org/10.1097/hjh.0b013e3283576faf.Vasunta R, Kesäniemi Y, Ylitalo A, Ukkola O. Primary nonalcoholic fatty liver disease in hypertensive patients. J Hypertens. 2012; 30: 2015–9. Available from: https://doi.org/10.1097/hjh.0b013e3283576faf.Latea L, Negrea S, Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. Aust Med J. 2013; 6: 325–30. Available from: https://doi.org/10.4066/AMJ.2013.1648.Latea L, Negrea S, Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. Aust Med J. 2013; 6: 325–30. Available from: https://doi.org/10.4066/AMJ.2013.1648.Стаценко М. Е., Стрельцова А. М., Туровец М. И. Влияние неалкогольной жировой болезни печени на показатели артериальной жесткости и риск сердечно-сосудистых осложнений у пациентов с артериальной гипертензией. Архив внутренней медицины. 2020; 10 (4): 296–304. DOI: 10.20514/2226-6704-2020-10-4-296-304.Statsenko ME, Streltsova AM, Turovets MI. Vlijanie nealkogol'noj zhirovoj bolezni pecheni na pokazateli arterial'noj zhestkosti i risk serdechno-sosudistyh oslozhnenij u pacientov s arterial'noj gipertenziej. Arhiv vnutrennej mediciny. 2020; 10 (4): 296–304. DOI: 10.20514/2226-6704-2020-10-4-296-304. Russian.Carnagarin R, Matthews V,. Zaldivia MTK, Peter K, Schlaich MP. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. British Journal of Pharmacology. 2019; 176 (12): 1839–52.Carnagarin R, Matthews V,. Zaldivia MTK, Peter K, Schlaich MP. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. British Journal of Pharmacology. 2019; 176 (12): 1839–52.Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008; 72: 618–25.Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008; 72: 618–25.Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonal-coholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015; 274: 693–701.Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonal-coholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015; 274: 693–701.Emre A, Terzi S, Celiker E, et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for STsegment elevation myocardial infarction. Am J Cardiol. 2015; 116: 1810–4.Emre A, Terzi S, Celiker E, et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for STsegment elevation myocardial infarction. Am J Cardiol. 2015; 116: 1810–4.Shi KQ, Wu FL, Liu WY, et al. Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. Mol Biol Rep. 2014; 41: 4713–20.Shi KQ, Wu FL, Liu WY, et al. Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. Mol Biol Rep. 2014; 41: 4713–20.Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla V. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017; 11: S209–S216. Available from: https://doi.org/10.1016/j.dsx.2016.12.033.Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla V. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017; 11: S209–S216. Available from: https://doi.org/10.1016/j.dsx.2016.12.033.Keskin M, Hayıroğlu M, Uzun A, et al. Effect of nonalco-holic fatty liver disease on in-hospital and long-term outcomes in patients with st-segment elevation myocardial infarction. Am J Cardiol. 2017; 120: 1720–6. Available from: https://doi.org/10.1016/j.amjcard.2017.07.107.Keskin M, Hayıroğlu M, Uzun A, et al. Effect of nonalco-holic fatty liver disease on in-hospital and long-term outcomes in patients with st-segment elevation myocardial infarction. Am J Cardiol. 2017; 120: 1720–6. Available from: https://doi.org/10.1016/j.amjcard.2017.07.107.Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014; 11: 639–54.Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014; 11: 639–54.Targher G, Mantovani A, Pichiri I, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond). 2013; 125: 301–9.Targher G, Mantovani A, Pichiri I, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond). 2013; 125: 301–9.Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PloS One. 2013; 8: e57183.Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PloS One. 2013; 8: e57183.Ozveren O, Izgi C, Eroglu E, et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty liver disease. UltrasonImaging. Epub. 07/08/2015.Ozveren O, Izgi C, Eroglu E, et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty liver disease. UltrasonImaging. Epub. 07/08/2015.Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014; 24: 663–9.Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014; 24: 663–9.Стаценко М. Е., Туркина С. В., Шилина Н. Н. Поражение печени у больных с хронической сердечной недостаточностью ишемического генеза и сахарным диабетом типа 2 — коварный тандем: возможности дополнительной органопротективной терапии. Consilium Medicum. 2016; 18 (5): 103–109.Stacenko M. E., Turkina S. V., Shilina N. N. Porazhenie pecheni u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju ishemicheskogo geneza i saharnym diabetom tipa 2 — kovarnyj tandem: vozmozhnosti dopolnitel'noj organoprotektivnoj terapii. Consilium Medicum. 2016; 18 (5): 103–109. Russian.Cassidy S, Hallsworth K, Thoma C, et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc Diabetol. 2015; 14: 23.Cassidy S, Hallsworth K, Thoma C, et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc Diabetol. 2015; 14: 23.VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015; 62: 773–83.VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015; 62: 773–83.Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fattyliver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012; 35: 389–95.Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fattyliver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012; 35: 389–95.Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Nonalcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest. 2012; 35: 215–8.Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Nonalcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest. 2012; 35: 215–8.Mantovani A, Pernigo M, Bergmini C, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Le. Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS ONE. 2015; 10 (8): 234–9. DOI: 10.1371/journal.pone.0135329.Mantovani A, Pernigo M, Bergmini C, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Le. Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS ONE. 2015; 10 (8): 234–9. DOI: 10.1371/journal.pone.0135329.Стаценко М. Е., Туркина С. В., Косивцова М. А. Возможности коррекции микроциркуляторных нарушений при неалкогольной жировой болезни печени у пациентов с хронической сердечной недостаточностью. Архив внутренней медицины. 2016; 6 (6): 42–47.Statsenko ME, Turkina SV, Kosivtsova MA. Vozmozhnosti korrekcii mikrocirkuljatornyh narushenij pri nealkogol'noj zhirovoj bolezni pecheni u pacientov s hronicheskoj serdechnoj nedostatochnost'ju. Arhiv vnutrennej mediciny. 2016; 6 (6): 42– 47. Russian.

The authors declare that there are no conflicts of interest present.